

DAFTAR PUSTAKA

1. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. *Am J Hematol* 2002;69:258 – 71.
2. Duffy TP. Autoimmune hemolytic anemia and paroxysmal nocturnal hemoglobinuria. In: Simon TL, Dzik WH, Synder EL, Stowell CP, Strauss RG, editors. *Rossi's Principles of Transfusion Medicine*. 3rd ed. Philadelphia, USA: Lippincott Williams and Wilkins Publication; 2002.
3. Pusparini, Wirawan R. Anemia Hemolitik Autoimun. *MKI*.2000;50:522 – 8.
4. Roumier M, Loustau V, Guillaud C, Languielle L, Mahevas M, Khellaf M, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on a single-center experience with 60 patients. *Am J Hematol*. 2014;89(9): 150 – 5.
5. Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Bona ED, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. *Blood*. 2014;124(19):2930 – 6.
6. Abramson N, Gelfand EW, Jandl JH, Rosen FS. The interaction between human monocytes and red cells. Specificity for IgG subclasses and IgG fragments. *J Exp Med*. 1970;132:1207 – 15.
7. Anderson CL, Looney RJ. Human leukocyte IgG Fc receptors. *Immunol Today* 1986;7:264.
8. Ravetch JV, Kinet JP. Fc receptors. *Annu Rev Immunol* 1991;9:457 – 92.
9. Barros MM, Langhi DM, Bordin JO. Autoimmune hemolytic anemia : transfusion challenges and solutions. *IJCTM*. 2017;(5) 9 – 18.
10. Klein H, Anstee DJ. ABO, lewis and P group and Ii antigen. In Mollison. *Blood Transfusion in Clinical Medicine*. 11th ed. London: Blackwell Pub; 2005. 114 – 62.
11. Barros MM, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. *Transfus Med Rev*. 2010;24(3):195 – 210.
12. Salama A, Berghöfer H, Mueller-Eckhardt C. Red blood cell transfusion in warm-type autoimmune haemolytic anaemia. *Lancet*. 1992; 340(8834–8835):1515 – 7.

13. Barros MM, Yamamoto M, Figueiredo MS. Expression levels of CD47, CD35, CD55, and CD59 on red blood cells and signal-regulatory protein-alpha,beta on monocytes from patients with warm autoimmune hemolytic anemia. *Transfusion*. 2009;49(1):154 – 60.
14. Marris KP, Naqvi N, Davies P, Smith M, Lee PW. A new formula for blood transfusion volume in the critically ill. *Arch Dis Child* 2005;90:724 – 8.
15. British Committee for Standards in Haematology. *Transfusion guidelines*. 2003.
16. Wiesen AR, Hospenthal DR, Byrd JC, Glass KL, Howard RS, Diehl LF. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. *Ann Intern Med*. 1994;121:278 – 80.
17. Hoque MM, Adnan SD, Karim S, Al Mamun MA, Nandy S, Faruki MA, et al. Equilibration and increase of hemoglobin concentration after one unit whole blood transfusion among patients not actively bleeding. *J Dhaka Med Coll*. 2014;23(2):161 – 6.
18. Chaudhary RK, Das SS. Autoimmune hemolytic anemia: From lab to bedside. *Asian J Transfus Sci* 2014;8:5 – 12.
19. Chiaroni J, Touinssi M, Mazet M, De Micco P, Ferrera V. Adsorption of autoantibodies in the presence of LISS to detect alloantibodies underlying warm autoantibodies. *Transfusion* 2003;43:651 – 5.
20. Das SS, Zaman RU, Safi M. Incompatible blood transfusion: challenging yet lifesaving in the management of acute severe autoimmune hemolytic anemia. *Asian J Transfus Sci*. 2014;8(2):105 – 8.
21. Watering LVD, Hermans J, Mituliet M, Versteegh M, Brand A. HLA and RBC immunization after filtered and buffy coat depleted blood transfusion in cardiac surgery : a randomized controlled trial. *Transfusion*. 2003;43:765 – 71.
22. Herawati S, Santhi DGD. Korelasi efikasi transfusi packed red cell dengan kejadian aloimunisasi eritrosit pada pasien anemia kronik. 2018.
23. Mollison PL, Engelfriet CP, Contreras M. *Blood transfusion in clinical medicine*. 10th ed. Oxford: Blackwell Scientific; 1997:79 – 89.
24. Aguilar RM, Ruiz SG, Ojeda JV, Cervantes LAM, Maldonado ER. Patophysiology of Alloimmunization. *Transfus Med Hemother*. 2020;47:152 – 9.

25. Yürek S, Mayer B, Almahallawi M, Pruss A, Salama A. Precautions surrounding blood transfusion in autoimmune haemolytic anaemias are overestimated. *Blood Transfus.* 2015;13(4):616 – 21.
26. Messih IYA, Mahmoud HM, Habashy DMM. Prevalence of red cell allo-antibodies among mutitransfusion autoimmune hemolytic anemia Egyptian patients. *J Appl Hematol* 2014;5:96 – 100.
27. Zumberg MS, Procter JL, Lottenberg R, Kitchens CS, Klein HG. Autoantibody formation in the alloimmunized red blood cell recipient: Clinical and laboratory implications. *Arch Intern Med* 2001;161:285 – 90.
28. Mayer B, Yurek S, Kiesewetter H, Salama A. Mixed-type autoimmune haemolytic anemia: differential diagnosis and a critical review of reported cases. *Transfusion.* 2008;48(10):2229 – 34.
29. Park SH, Choe WH, Kwon SW. Red blood cell transfusion in patients with autoantibodies: is it effective and safe without increasing hemolysis risk? *Ann Lab Med.* 2015;35(4):436 – 44.
30. Wikman A, Axdorph U, Gryfelt G, Gustafsson L, Björkholm M, Lundahl J. Characterization of red cell autoantibodies in consecutive DAT-positive patients with relation to in vivo haemolysis. *Ann Hematol.* 2005;84(3):150 – 58.
31. Booth C, Allard S. Blood transfusion. *Transfusion Medicine.* 2017; 28(4): 1 – 7.
32. Kumar H, Gupta P, Mishra D, Sarkar R, Jaiprakash M. Leucodepletion and blood products. *M JAFI.* 2006; 62(2): 174 – 7.
33. Bianchi M, Vaglio S, Pupella S, Marano G, Facco G, Liunbruno GM, et al. Leucoreduction of blood components : an effective way to increase blood safety? *Blood Transfus.* 2016; 14: 214 – 27.
34. Sharma R, Neelam M. Leukoreduced blood components : advantages and strategies for its implementation in developing countries. *Asian J Transfusions Sci.* 2010; 4(1): 3 – 8.
35. You J, Jiang X, Zhu A. The study of leukocyte filtration in preventing platelet transfusion refractoriness. *J Clin Transfus Lab Med.* 2012; 14(4): 295 – 7.
36. Gombotz H, Dehkharghany A. Clinical consequences of leukocyte reduction. *ESA.* 2004; (1): 235 – 40.

37. Park SH. Diagnosis and treatment of autoimmune hemolytic anemia: classic approach and recent advances. *Blood Research* 2016;51:69 – 71.
38. Widayati K, Hariadi, Pradjono E. Anemia hemolitik imun. Dalam Setiati S, Alwi I, Sudoyo AW, Simodibrata M, Setryahadi M, Syam AF. *Buku Ajar Ilmu Penyakit Dalam Jilid II Edisi VI*. Balai Penerbit FK UI. Jakarta;2007:2607 – 13.
39. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. *Haematologica*. 2014;99:1547 – 52.
40. Rodrigo C, Rajapakse S, Gooneratne L. Rituximab in the treatment of autoimmune haemolytic anemia. *Blood Research* 2014;42:2331 – 45.
41. Zeerleder S. Autoimmune hemolytic anemia - a practical guide to cope with a diagnostic and therapeutic challenge. *The Journal of Medicine*.2011;69:177 – 82.
42. Barcellini W, Fattizzo B. Autoimmune hemolytic anemia - progress in emerging treatment options. *Expert Opinion on Orphan Drugs* 2018:1 – 7.
43. DeLoughery TG. Autoimmune hemolytic anemia. *Hematology* 2013;8:2 – 9.
44. Lechner K, Jager U. How i treat autoimmune hemolytic anemia in adults. *Blood Journal* 2010;1:5 – 10.
45. Brecher,M.E. Technical Manual. 15th Ed. USA : American Association of Blood Banks (AABB).2005. 483 – 520.
46. Klein HG, Anstee DJ, Mollison. *Blood transfusion in clinical medicine*. Mollison,s 11th ed. Philadelphia : Blackwell Publishing. 2005. 48 – 114.
47. Hebert,P.C., Tinmouth,A., Carson,J.L. Red cell transfusion in perioperative and critically ill patients. *Blood Banking and Transfusion Medicine* 2nd ed. Philadelphia : Elsevier Inc.2007. 445 – 54.
48. Regan FAM. Blood cell antigens and antibodies : erythrocytes, platelets and neutrophils. *Practical Haematology* 12th ed. Elsevier. 2017: 447 – 50.
49. Tormey CA, Hendrickson JE. Transfusion-related red blood cell alloantibodies: induction and Consequences. *ASH*. 2019.
50. Bhuva DK , Vachhani JH. Red Cell alloimmunization in repeatedly transfusion patients. *Asian J Transfus Sci*.2017; 11 (2) : 115 – 20.
51. Schroeder HW, Cavacini L. Structure and function of immunoglobulins. *J. Allergy Clin. Immunol*. 2010. 125:41 – 52.

52. Palmeira PC, Quinello AL, Silveira LCA, Zago, Carneiro-Sampaio. IgG placental transfer in healthy and pathological pregnancies. *Clin. Dev. Immunol.* 2012. 985646.
53. Lucas AH. IgG subclass-restricted immune responses to allergens. *Springer Semin. Immunopathol.*1990. 12:385 – 90.
54. Zupanska BA. Cellular bioassays and their use in predicting the clinical significance of antibodies. In: Garratty G, editor. *Immunobiology of transfusion medicine.* New York: Marcel Dekker; 1994:465 – 92.
55. Guyre PM, Miller R. Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes. *J Clin Invest* 1983;72:393 – 7.
56. Yount WJ, Dorner MM, Kunkel HG, Kabat EA. Studies on human antibodies: Selective variations in subgroup composition and genetic markers. *J. Exp. Med.*1968.127:633 – 46.
57. Amlot PL, Hayes AE, Gray D, Gordon-Smith EC, Humphrey JH. Human immune responses in vivo to protein (KLH) and polysaccharide (DNP-Ficoll) neoantigens: normal subjects compared with bone marrow transplant patients on cyclosporine. *Clin. Exp. Immunol.*1986. 64:125 – 35.
58. DeKruyff RH, Mosmann RR, Umetsu DT. Induction of antibody synthesis by CD4⁺ T cells: IL 5 is essential for induction of antigen-specific antibody responses by TH2 but not TH1 clones. *Eur. J. Immunol.* 1990. 20:2219 – 27.
59. Kawasaki YJ, Suzuki N, Sakai M, Isome R, Nozawa M, Tanji, et al. Evaluation of T helper-1/2 balance on the basis of IgG subclasses and serum cytokines in children with glomerulonephritis. *Am. J. Kidney Dis.* 2004.44:42 – 9.
60. Bettelli EY, Carrier W, Gao, T. Korn, T. B. Strom, M. Oukka, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. *Nature.* 2006. 441(7090): 235 – 38.
61. Pene JJ, Gauchat F, Lecart S, Drouet E, Guglielmi P, Boulay V, et al. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. *J. Immunol.* 2004. 172:5154 – 7.

62. Segel GB, Lichtman, MA. Direct antiglobulin ("Coombs") test-negative autoimmune hemolytic anemia: a review. *Blood Cells, Molecules, and Diseases*, 2014 52, 152 – 60.
63. Thedsawad A, Taka O, Wanachiwanawin W. Significances of red cell bound immunoglobulin G as detected by flow cytometry in patients with Coombs-negative immune hemolysis. *Transfusion Medicine*, 2016, 26 : 130 – 7.
64. Hirano A, Yamada H, Kato K. Quantitation of red-cell-bound IgG in normal and pathologic states by an enzyme immunoassay (EIA) technique. *NJMS*, 1985, 47:5 – 16.
65. Valenta RI, Mittermann T, Werfel H, Garn, Renz H. Linking allergy to autoimmune disease. *Trends Immunol.* 2009. 30:109 – 16.
66. Sweeney J, Heaton A. Clinical benefits of leukodepleted blood products Germany: Springer-Verlag; 1995. 45 – 71.
67. Bruil A, Beugeling T, Feijen J, Aken WGV. The mechanisms of leukocyte removal by filtration. *Trans Med Rev.* 1995; IX(2): 145 – 66.
68. Kalfa TA. Warm antibody autoimmune hemolytic anemia. When Antibody Response Goes Awry. *ASH.* 2016:690 – 96.
69. Pandey H, Das SS, Chaudary R. Red cell alloimmunization in transfused patients : A silent epidemic revisited. *AJCTS.* 2014.8:75 – 7.
70. Atmakusuma D, Rajabto D, Setiati S. Profil pasien anemia hemolitik autoimun (AHAI) dan repon pengobatan pasca terapi kortikosteroid di rumah sakit umum pusat nasional dr. Cipto Mangunkusumo. *JPDI.* 2016;4(3).

